EGFR and non-small cell lung carcinoma: Another randomized, phase 3 study (OPTIMAL) [20, 21] undertaken in China also confirmed the superiority of erlotinib than first-line chemotherapy in NSCLC patients harboring EGFR mutation (13·1 vs 4·6 months; HR 0·16, 95% CI 0·10–0·26; p < 0·0001)